fig1

Figure 1. EGFR mutations identified in NSCLC.(A) Mutations associated with sensitivity to TKIs (top) andmutations associated with resistance to TKIs (bottom); (B) mutations isolated from NSCLC tumors with unclear association with response to erlotinib or gefitinib. X: multiple substitutions have been reported at an amino acid; P: P-loop; A: activation domain; α-C: α-C helix domain; EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinases inhibitor